Related Articles
Efficacy and safety of camrelizumab (a PD‑1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non‑small cell lung cancer
Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer
Thyroid dysfunction during PD‑1 inhibitor treatment in patients with cancer: Incidence and association with progression‑free survival
Indirect comparison of the efficacy and safety of gefitinib and cetuximab‑based therapy in patients with advanced non‑small‑cell lung cancer
Immune‑related genes and gene sets for predicting the response to anti‑programmed death 1 therapy in patients with primary or metastatic non‑small cell lung cancer